Drugs / Secretome-MSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04753476 | Jun 2020 → Feb 2022 | COVID-19, cytokine release syndrome | Stem Cell and Cancer Research Indonesia | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Secretome-MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04753476 ↗ |
| Known as | S-MSCs | “active soluble molecules known as Secretome-MSCs (S-MSCs), such as IL-10 and TGF-β that useful in alleviating inflammation.” NCT04753476 ↗ |
| Route | Intramuscular | “Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus)” NCT04753476 ↗ |